Effect of Vildagliptin on Adipose Tissue and Skeletal Muscle Metabolism in Obese Patients With Type 2 Diabetes.

Trial Profile

Effect of Vildagliptin on Adipose Tissue and Skeletal Muscle Metabolism in Obese Patients With Type 2 Diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 04 May 2012 Actual end date (1 Apr 2007) added as reported by ClinicalTrials.gov.
    • 01 Mar 2009 Results published in Journal of Clinical Endocrinology and Metabolism 94: 846-852, No. 3, Mar 2009
    • 11 Sep 2008 Results have been published in the proceedings of the 44th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top